Latin America Point Of Care (PoC) Diagnostics Market Analysis By Product (Glucose Testing, Hb1Ac Testing, Coagulation, Fertility, Cardiac Markers, Infectious Diseases, Primary Acre Systems, Hematology, Decentralized Clinical Chemistry, Feces, Blood Gas Electrolytes, Ambulatory Chemistry, Urinalysis, Drug Abuse Testing, HIV, Clostridium Difficile, HBV, Pneumonia Or Streptococcus Associated Infections) By End-Use (Clinics, Hospital, Home), And Segment Forecasts To 2024
Latin America point of care diagnostics market to reach USD 1.73 billion by 2024, according to a new report by Grand View Research, Inc. Penetration of major key players in Latin American countries coupled with increased initiatives by government and academic institutes towards retaining the spread of chronic diseases is expected to fuel market growth through to 2024.
Moreover, increaseddensity of geriatric population in the countries and immigration of retired people from Northern and Central America to this region looking forward towards assisted living healthcare and home health care is anticipated to propel growth in the coming years.Furthermore, owing to increased geriatric population prevalence of chronic, endemic and infectious diseases is high in LAC which is expected to increase the market potential through to 2024.
Further key findings from the report suggest:
Owing to the higher prevalence of diabetes, glucose testing was estimated to have highest share in revenue in 2015. Substantial increase in adoption of products pertaining to glucose testing and rise in number of major players in addition to local manufacturers in developing countries of Latin Americanare factors attributive to contribute stable contribution to segment revenue generation.
Hb1Ac POC test is the second highest contributor to the market share with respect to revenue. This segment is expected to grow at a CAGR faster than glucose testing owing to itsreliability and rapidly increased patient base for diabetes management.
High prevalence of endemic infectious disease along with positive potential for emergence of new diseases like Ebola make infectious disease testing another segment of prime activity in Latin America point of care market. This segment includes rapid diagnostic tests for a considerable number of infectious diseases like HIV, Influenza/Flu, Clostridium Difficile, HBV, HPV, Pneumonia Or Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV), HCV, MRSA, TB And Drug-Resistant TB, HSV, Ebola, Cryptosporidiosis, E.Histolytica, Syphilis, Legionella/Legionnaires’ Disease, Adenovirus Infections, Trichomonas, Rubella
Growing prevalence of a number of infectious diseases in lower economy countries like Haiti, Bolivia, Guatemala, and others in addition to rapid spread of STDs in developing economies of Brazil, Mexico, and Chile is expected to propel the need for POC diagnostics over the forecast period. Further, number of initiatives by government for early screening and diagnosis of the diseases, and support to set up health checkups and camps is anticipated to contribute towards rise in demand.
Clinics are estimated to dominate the Latin America POC diagnostics industry with respect to end user owing to the increased awareness for health care among the population and initiatives by international healthcare organizations and number of governments to control the spread of diseases in this region. Owing to increased availability of products and comparative rise in usage rate for disease monitoring and diagnosis the segment is expected to generate lucrative revenue for the market.
Brazil dominated Latin America POC diagnostics industry in 2015, with an estimated share in revenue of over 35%. Presence of healthcare reforms like Unified Health System (SUS) is expected to fuel the market growth in Brazil. high prevalence of infections and rapid increase in incidences of diabetes, cancer and cardiac disorders in the country is anticipated to rise demand for POC diagnostics.
Chile is estimated to witness potential growth in the coming years owing to emergence of Zika virus in addition to higher prevalence of Chagas disease. Developments carried out in the economy in order to develop the healthcare infrastructure, control and reduce the incidence of target diseases along with preventing emergence of new diseases are expected to boost the demand for POC diagnostics in this country.
Major participants in this industry include Abbott Laboratories, Alere Inc (Abbott), Roche Diagnostics, Bio-rad Laboratories, Danaher Corporation, bioMerieux, Agilent Technologies, Inc., OraSure Technologies Inc, Siemens Healthineers, Abaxis Inc.
Strategies by participants to maintain competitive advantage over others in the industry to enhance the market presence is expected to enhance market growth in this region. Initiatives by government to bring together manufacturers, healthcare service providers and research institutes are anticipated to maintain revenue generation for industry.
For instance, in May 2016, Chembio Diagnostics announced to introduce a POC diagnostic test for Zika virus in Brazil. In addition to this the company is also working in collaboration with Bio-Manguinhos for over 12 years and has developed and commercialized POC tests for HIV, Leishmania, and Syphilis
Moreover, increaseddensity of geriatric population in the countries and immigration of retired people from Northern and Central America to this region looking forward towards assisted living healthcare and home health care is anticipated to propel growth in the coming years.Furthermore, owing to increased geriatric population prevalence of chronic, endemic and infectious diseases is high in LAC which is expected to increase the market potential through to 2024.
Further key findings from the report suggest:
Owing to the higher prevalence of diabetes, glucose testing was estimated to have highest share in revenue in 2015. Substantial increase in adoption of products pertaining to glucose testing and rise in number of major players in addition to local manufacturers in developing countries of Latin Americanare factors attributive to contribute stable contribution to segment revenue generation.
Hb1Ac POC test is the second highest contributor to the market share with respect to revenue. This segment is expected to grow at a CAGR faster than glucose testing owing to itsreliability and rapidly increased patient base for diabetes management.
High prevalence of endemic infectious disease along with positive potential for emergence of new diseases like Ebola make infectious disease testing another segment of prime activity in Latin America point of care market. This segment includes rapid diagnostic tests for a considerable number of infectious diseases like HIV, Influenza/Flu, Clostridium Difficile, HBV, HPV, Pneumonia Or Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV), HCV, MRSA, TB And Drug-Resistant TB, HSV, Ebola, Cryptosporidiosis, E.Histolytica, Syphilis, Legionella/Legionnaires’ Disease, Adenovirus Infections, Trichomonas, Rubella
Growing prevalence of a number of infectious diseases in lower economy countries like Haiti, Bolivia, Guatemala, and others in addition to rapid spread of STDs in developing economies of Brazil, Mexico, and Chile is expected to propel the need for POC diagnostics over the forecast period. Further, number of initiatives by government for early screening and diagnosis of the diseases, and support to set up health checkups and camps is anticipated to contribute towards rise in demand.
Clinics are estimated to dominate the Latin America POC diagnostics industry with respect to end user owing to the increased awareness for health care among the population and initiatives by international healthcare organizations and number of governments to control the spread of diseases in this region. Owing to increased availability of products and comparative rise in usage rate for disease monitoring and diagnosis the segment is expected to generate lucrative revenue for the market.
Brazil dominated Latin America POC diagnostics industry in 2015, with an estimated share in revenue of over 35%. Presence of healthcare reforms like Unified Health System (SUS) is expected to fuel the market growth in Brazil. high prevalence of infections and rapid increase in incidences of diabetes, cancer and cardiac disorders in the country is anticipated to rise demand for POC diagnostics.
Chile is estimated to witness potential growth in the coming years owing to emergence of Zika virus in addition to higher prevalence of Chagas disease. Developments carried out in the economy in order to develop the healthcare infrastructure, control and reduce the incidence of target diseases along with preventing emergence of new diseases are expected to boost the demand for POC diagnostics in this country.
Major participants in this industry include Abbott Laboratories, Alere Inc (Abbott), Roche Diagnostics, Bio-rad Laboratories, Danaher Corporation, bioMerieux, Agilent Technologies, Inc., OraSure Technologies Inc, Siemens Healthineers, Abaxis Inc.
Strategies by participants to maintain competitive advantage over others in the industry to enhance the market presence is expected to enhance market growth in this region. Initiatives by government to bring together manufacturers, healthcare service providers and research institutes are anticipated to maintain revenue generation for industry.
For instance, in May 2016, Chembio Diagnostics announced to introduce a POC diagnostic test for Zika virus in Brazil. In addition to this the company is also working in collaboration with Bio-Manguinhos for over 12 years and has developed and commercialized POC tests for HIV, Leishmania, and Syphilis
CHAPTER 1 RESEARCH METHODOLOGY & SCOPE
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET SNAPSHOT
CHAPTER 4 MARKET VARIABLES, TRENDS& SCOPE
4.1 Market segmentation& scope
4.1.1 Market Driver Analysis
4.1.1.1 Increased awareness pertaining to medical status among the people
4.1.1.2 Penetration of key market entities in Latin America
4.1.1.3 Growing demand for home healthcare and the introduction of advance technology enabled products
4.1.1.4 Growing geriatric population base
4.1.1.5 Growing prevalence of target diseases
4.1.2 Market Restraint Analysis
4.1.2.1 High procedure costs
4.1.2.2 High cost for product accession
4.2 Penetration & growth prospect mapping
4.3 Point of care diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
4.4 Industry Analysis - Porter’s
4.5 Product positioning Analysis
CHAPTER 5 MARKET CATEGORIZATION 1: PRODUCT ESTIMATES & TREND ANALYSIS
5.1 Latin America point of care diagnostics market: Product movement analysis
5.2 Glucose testing
5.2.1 Glucose testing market, 2013 - 2024 (USD Million)
5.3 Hb1Ac Testing
5.3.1 Hb1Ac testing market, 2013 - 2024 (USD Million)
5.4 Coagulation testing
5.4.1 Coagulationtesting market, 2013 - 2024 (USD Million)
5.5 Fertility testing
5.5.1 Fertilty testing market, 2013 - 2024 (USD Million)
5.6 Cardiac markers
5.6.1 Cardiac markers market, 2013 - 2024 (USD Million)
5.7 Infectious disaese testing
5.7.1 Infectious disease testing market, 2013 - 2024 (USD Million)
5.7.2 HIV POC
5.7.2.1 HIV POC market, 2013 - 2024 (USD Million)
5.7.3 Clostridium difficile POC
5.7.3.1 Clostridium difficile POC market, 2013 - 2024 (USD Million)
5.7.4 HBV POC
5.7.4.1 HBV POC market, 2013 - 2024 (USD Million)
5.7.5 Pneumonia or Streptococcus associated infections
5.7.5.1 Pneumonia or Streptococcus associated infections market, 2013 - 2024 (USD Million)
5.7.6 Respiratory syncytial virus (RSV) POC
5.7.6.1 Respiratory syncytial virus (RSV) POC market, 2013 - 2024 (USD Million)
5.7.7 HPV POC
5.7.7.1 HPV POC market, 2013 - 2024 (USD Million)
5.7.8 Influenza/Flu POC
5.7.8.1 Influenza/Flu POC market, 2013 - 2024 (USD Million)
5.7.9 HCV POC
5.7.9.1 HCV POC market, 2013 - 2024 (USD Million)
5.7.10 MRSA POC
5.7.10.1 MRSA POC market, 2013 - 2024 (USD Million)
5.7.11 TB and drug-resistant TB POC
5.7.11.1 TB and drug-resistant TB POC market, 2013 - 2024 (USD Million)
5.7.12 HSV POC
5.7.12.1 HSV POC market, 2013 - 2024 (USD Million)
5.7.13 Other Infectious Diseases
5.7.13.1 Other Infectious Diseases market, 2013 - 2024 (USD Million)
5.8 Primary care systems
5.8.1 Primary care systemsmarket, 2013 - 2024 (USD Million)
5.9 Heamatology testing
5.9.1 Hematology testing market, 2013 - 2024 (USD Million)
5.10 Decentralized clinical chemistry
5.10.1 Decentralized clinical chemistry market, 2013 - 2024 (USD Million)
5.11 Blood gas/electrolytes testing
5.11.1 Blood gas/electrolytes testing market, 2013 - 2024 (USD Million)
5.12 Ambulatory chemistry
5.12.1 Ambulatory chemistry market, 2013 - 2024 (USD Million)
5.13 Urinanalysis
5.13.1 Urinanalysis market, 2013 - 2024 (USD Million)
5.14 Drug abuse testing
5.14.1 Drug abuse testing market, 2013 - 2024 (USD Million)
CHAPTER 6 MARKET CATEGORIZATION 2: END-USE ESTIMATES & TREND ANALYSIS
6.1 Latin America point of care diagnostics market:end-use movement analysis
6.2 Clinics
6.2.1 Clinics market, 2013 - 2024 (USD Million)
6.3 Hospitals
6.3.1 Hospitals market, 2013 - 2024 (USD Million)
6.4 Home
6.4.1 Home market, 2013 - 2024 (USD Million)
6.5 Assiated living healthcare facilities
6.5.1 Assiated living healthcare facilities market, 2013 - 2024 (USD Million)
6.6 Laboratories
6.6.1 Laboratories market, 2013 - 2024 (USD Million)
6.7 Others
6.7.1 Other end-use market, 2013 - 2024 (USD Million)
CHAPTER 7 MARKET CATEGORIZATION 3: REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT, & END-USE
7.1 Latin America point of care diagnostics market share by region, 2015 & 2024
7.2 Brazil
7.2.1 Brazil point of care diagnostics market, 2013 - 2024 (USD Million)
7.3 Mexico
7.3.1 Mexico point of care diagnostics market, 2013 - 2024 (USD Million)
7.4 Chile
7.4.1 Chile point of care diagnostics market, 2013 - 2024 (USD Million)
7.5 Argentina
7.5.1 Argentina point of care diagnostics market, 2013 - 2024 (USD Million)
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Strategy framework
8.2 Market participation categorization
8.3 Company Profiles
8.3.1 Abbott Laboratories
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Alere Inc (Abbott)
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Roche Diagnostics
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Bio-rad Laboratories
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 Danaher Corporation
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 bioMerieux
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Agilent Technologies, Inc.
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 OraSure Technologies Inc
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 Siemens Healthineers
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Abaxis Inc.
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET SNAPSHOT
CHAPTER 4 MARKET VARIABLES, TRENDS& SCOPE
4.1 Market segmentation& scope
4.1.1 Market Driver Analysis
4.1.1.1 Increased awareness pertaining to medical status among the people
4.1.1.2 Penetration of key market entities in Latin America
4.1.1.3 Growing demand for home healthcare and the introduction of advance technology enabled products
4.1.1.4 Growing geriatric population base
4.1.1.5 Growing prevalence of target diseases
4.1.2 Market Restraint Analysis
4.1.2.1 High procedure costs
4.1.2.2 High cost for product accession
4.2 Penetration & growth prospect mapping
4.3 Point of care diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
4.4 Industry Analysis - Porter’s
4.5 Product positioning Analysis
CHAPTER 5 MARKET CATEGORIZATION 1: PRODUCT ESTIMATES & TREND ANALYSIS
5.1 Latin America point of care diagnostics market: Product movement analysis
5.2 Glucose testing
5.2.1 Glucose testing market, 2013 - 2024 (USD Million)
5.3 Hb1Ac Testing
5.3.1 Hb1Ac testing market, 2013 - 2024 (USD Million)
5.4 Coagulation testing
5.4.1 Coagulationtesting market, 2013 - 2024 (USD Million)
5.5 Fertility testing
5.5.1 Fertilty testing market, 2013 - 2024 (USD Million)
5.6 Cardiac markers
5.6.1 Cardiac markers market, 2013 - 2024 (USD Million)
5.7 Infectious disaese testing
5.7.1 Infectious disease testing market, 2013 - 2024 (USD Million)
5.7.2 HIV POC
5.7.2.1 HIV POC market, 2013 - 2024 (USD Million)
5.7.3 Clostridium difficile POC
5.7.3.1 Clostridium difficile POC market, 2013 - 2024 (USD Million)
5.7.4 HBV POC
5.7.4.1 HBV POC market, 2013 - 2024 (USD Million)
5.7.5 Pneumonia or Streptococcus associated infections
5.7.5.1 Pneumonia or Streptococcus associated infections market, 2013 - 2024 (USD Million)
5.7.6 Respiratory syncytial virus (RSV) POC
5.7.6.1 Respiratory syncytial virus (RSV) POC market, 2013 - 2024 (USD Million)
5.7.7 HPV POC
5.7.7.1 HPV POC market, 2013 - 2024 (USD Million)
5.7.8 Influenza/Flu POC
5.7.8.1 Influenza/Flu POC market, 2013 - 2024 (USD Million)
5.7.9 HCV POC
5.7.9.1 HCV POC market, 2013 - 2024 (USD Million)
5.7.10 MRSA POC
5.7.10.1 MRSA POC market, 2013 - 2024 (USD Million)
5.7.11 TB and drug-resistant TB POC
5.7.11.1 TB and drug-resistant TB POC market, 2013 - 2024 (USD Million)
5.7.12 HSV POC
5.7.12.1 HSV POC market, 2013 - 2024 (USD Million)
5.7.13 Other Infectious Diseases
5.7.13.1 Other Infectious Diseases market, 2013 - 2024 (USD Million)
5.8 Primary care systems
5.8.1 Primary care systemsmarket, 2013 - 2024 (USD Million)
5.9 Heamatology testing
5.9.1 Hematology testing market, 2013 - 2024 (USD Million)
5.10 Decentralized clinical chemistry
5.10.1 Decentralized clinical chemistry market, 2013 - 2024 (USD Million)
5.11 Blood gas/electrolytes testing
5.11.1 Blood gas/electrolytes testing market, 2013 - 2024 (USD Million)
5.12 Ambulatory chemistry
5.12.1 Ambulatory chemistry market, 2013 - 2024 (USD Million)
5.13 Urinanalysis
5.13.1 Urinanalysis market, 2013 - 2024 (USD Million)
5.14 Drug abuse testing
5.14.1 Drug abuse testing market, 2013 - 2024 (USD Million)
CHAPTER 6 MARKET CATEGORIZATION 2: END-USE ESTIMATES & TREND ANALYSIS
6.1 Latin America point of care diagnostics market:end-use movement analysis
6.2 Clinics
6.2.1 Clinics market, 2013 - 2024 (USD Million)
6.3 Hospitals
6.3.1 Hospitals market, 2013 - 2024 (USD Million)
6.4 Home
6.4.1 Home market, 2013 - 2024 (USD Million)
6.5 Assiated living healthcare facilities
6.5.1 Assiated living healthcare facilities market, 2013 - 2024 (USD Million)
6.6 Laboratories
6.6.1 Laboratories market, 2013 - 2024 (USD Million)
6.7 Others
6.7.1 Other end-use market, 2013 - 2024 (USD Million)
CHAPTER 7 MARKET CATEGORIZATION 3: REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT, & END-USE
7.1 Latin America point of care diagnostics market share by region, 2015 & 2024
7.2 Brazil
7.2.1 Brazil point of care diagnostics market, 2013 - 2024 (USD Million)
7.3 Mexico
7.3.1 Mexico point of care diagnostics market, 2013 - 2024 (USD Million)
7.4 Chile
7.4.1 Chile point of care diagnostics market, 2013 - 2024 (USD Million)
7.5 Argentina
7.5.1 Argentina point of care diagnostics market, 2013 - 2024 (USD Million)
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Strategy framework
8.2 Market participation categorization
8.3 Company Profiles
8.3.1 Abbott Laboratories
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Alere Inc (Abbott)
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Roche Diagnostics
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Bio-rad Laboratories
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 Danaher Corporation
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 bioMerieux
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Agilent Technologies, Inc.
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 OraSure Technologies Inc
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 Siemens Healthineers
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Abaxis Inc.
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
LIST OF TABLES
Table 1 Country share estimation
Table 2 Market driver relevance analysis (Current & future impact)
Table 3 Market restraint relevance analysis (Current & future impact)
Table 4 Latin America point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 5 Latin America point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 6 Latin America point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 7 Latin America point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 8 Latin America point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 9 Latin America point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 10 Brazil point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 11 Brazil point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 12 Brazil point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 13 Brazil point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 14 Brazil point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 15 Brazil point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 16 Mexico point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 17 Mexico point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 18 Mexico point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 19 Mexico point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 20 Mexico point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 21 Mexico point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 22 Chile point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 23 Chile point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 24 Chile point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 25 Chile point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 26 Chile point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 27 Chile point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 28 Argentina point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 29 Argentina point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 30 Argentina point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 31 Argentina point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 32 Argentina point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 33 Argentina point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 1 Country share estimation
Table 2 Market driver relevance analysis (Current & future impact)
Table 3 Market restraint relevance analysis (Current & future impact)
Table 4 Latin America point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 5 Latin America point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 6 Latin America point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 7 Latin America point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 8 Latin America point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 9 Latin America point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 10 Brazil point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 11 Brazil point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 12 Brazil point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 13 Brazil point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 14 Brazil point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 15 Brazil point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 16 Mexico point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 17 Mexico point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 18 Mexico point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 19 Mexico point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 20 Mexico point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 21 Mexico point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 22 Chile point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 23 Chile point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 24 Chile point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 25 Chile point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 26 Chile point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 27 Chile point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 28 Argentina point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 29 Argentina point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 30 Argentina point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 31 Argentina point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 32 Argentina point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 33 Argentina point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
